PL2046787T3 - Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4 - Google Patents

Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4

Info

Publication number: PL2046787T3
Authority: PL; Poland
Prior art keywords: pyrazolo; salt; pde4 inhibitors; pyridine compounds; allergic
Prior art date: 2006-08-01

Application number

PL07766400T

Other languages

English (en)

Inventor

David George Allen

Nicola Mary Aston

Rodger Phillip Barnett

Reshma Manesh Chudasama

Caroline Jane Day

Christopher David Edlin

Leanda Jane Kindon

Naimisha Trivedi

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-01

Filing date

2007-07-31

Publication date

2011-10-31

2006-08-01 Priority claimed from GB0615286A external-priority patent/GB0615286D0/en

2007-04-05 Priority claimed from GB0706790A external-priority patent/GB0706790D0/en

2007-07-30 Priority claimed from GB0714815A external-priority patent/GB0714815D0/en

2007-07-31 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2011-10-31 Publication of PL2046787T3 publication Critical patent/PL2046787T3/pl

Links

229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
150000005230 pyrazolo[3,4-b]pyridines Chemical class 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
206010039085 Rhinitis allergic Diseases 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
230000000172 allergic effect Effects 0.000 abstract 1
201000010105 allergic rhinitis Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
DEPWAGNOLISJQB-UHFFFAOYSA-N n-[[1,6-diethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]methyl]-4-[8-[2-hydroxyethyl(methyl)amino]octanoylamino]benzamide Chemical compound C=1C=C(NC(=O)CCCCCCCN(C)CCO)C=CC=1C(=O)NCC=1C(CC)=NC=2N(CC)N=CC=2C=1NC1CCOCC1 DEPWAGNOLISJQB-UHFFFAOYSA-N 0.000 abstract 1
208000037916 non-allergic rhinitis Diseases 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
206010039083 rhinitis Diseases 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL07766400T 2006-08-01 2007-07-31 Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4 PL2046787T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB0615286A GB0615286D0 (en)	2006-08-01	2006-08-01	Compounds
GB0706790A GB0706790D0 (en)	2007-04-05	2007-04-05	Compounds
GB0714815A GB0714815D0 (en)	2007-07-30	2007-07-30	Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
EP07766400A EP2046787B1 (en)	2006-08-01	2007-07-31	Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
PCT/GB2007/002908 WO2008015416A1 (en)	2006-08-01	2007-07-31	Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors

Publications (1)

Publication Number	Publication Date
PL2046787T3 true PL2046787T3 (pl)	2011-10-31

Family

ID=38996907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07766400T PL2046787T3 (pl)	2006-08-01	2007-07-31	Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4

Country Status (17)

Country	Link
US (3)	US20090325952A1 (pl)
EP (1)	EP2046787B1 (pl)
JP (1)	JP2009545579A (pl)
AT (1)	ATE504586T1 (pl)
AU (1)	AU2007280214A1 (pl)
CA (1)	CA2659539A1 (pl)
CL (1)	CL2007002349A1 (pl)
CY (1)	CY1111625T1 (pl)
DE (1)	DE602007013762D1 (pl)
DK (1)	DK2046787T3 (pl)
HR (1)	HRP20110434T1 (pl)
NZ (1)	NZ574533A (pl)
PL (1)	PL2046787T3 (pl)
PT (1)	PT2046787E (pl)
SI (1)	SI2046787T1 (pl)
TW (1)	TW200840818A (pl)
WO (2)	WO2008015416A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090325952A1 (en) *	2006-08-01	2009-12-31	Glaxo Group Limited	Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
KR20120006059A (ko) *	2009-04-17	2012-01-17	메르츠 파마 게엠베하 운트 코. 카가아	1-아미노-1,3,3,5,5-펜타메틸사이클로헥산 메실레이트의 합성
US8367829B2 (en)	2010-05-10	2013-02-05	Gilead Sciences, Inc.	Bi-functional pyrazolopyridine compounds
US9597312B2 (en) *	2010-08-19	2017-03-21	Cognitive Research Enterprises, Inc.	Treatment of cognitive disorders associated with abnormal dendritic spines using PKC activators
EP2628730B1 (en) *	2012-02-16	2017-12-06	Noxell Corporation	Telescoping synthesis of 5-amino-4-nitroso-1-alkyl-1h-pyrazole salts
US9011934B2 (en)	2013-06-14	2015-04-21	SatisPharma, LLC	Multi-purpose anti-itch treatment
US9452178B1 (en)	2014-10-22	2016-09-27	SatisPharma, LLC	Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
DE102015000626A1 (de) *	2015-01-22	2016-07-28	Kibion Gmbh	Verfahren zum Nachweis von Helicobacter Pylori
CN111732543A (zh) *	2020-08-14	2020-10-02	浙江鼎龙科技有限公司	一种4,5-二氨基-1-（2-羟乙基）吡唑硫酸盐的制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3200123A (en)	1962-01-26	1965-08-10	Richardson Merreil Inc	Imidazoquinolines
JPS4824396B1 (pl)	1970-09-09	1973-07-20
JPS56138200A (en)	1980-02-15	1981-10-28	Glaxo Group Ltd	Androstane carbothioate compound
DE3927761C2 (de)	1989-08-23	1997-11-27	Huels Chemische Werke Ag	Verfahren zur Herstellung von Alkoxyalkylidenmalonsäureestern
DE3931041C2 (de)	1989-09-16	2000-04-06	Boehringer Ingelheim Kg	Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
GB9127376D0 (en)	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
DE69435280D1 (de)	1993-03-10	2010-04-15	Glaxosmithkline Llc	Phosphodiesterase des menschlichen Gehirns und Screening-Verfahren
KR100321649B1 (ko)	1993-03-17	2002-07-22	미네소타 마이닝 앤드 매뉴팩춰링 캄파니	에스테르,아미드또는머캅토에스테르로부터유도된분산보조제를함유하는에어로졸제제
CN1070849C (zh)	1994-06-15	2001-09-12	惠尔康基金会集团公司	酶抑制剂
WO1996040640A1 (en)	1995-06-07	1996-12-19	Pfizer Inc.	BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
US6110934A (en)	1996-06-17	2000-08-29	Smithkline Beecham P.L.C.	Substituted benzamide derivatives and their use as anticonvulsants
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
US6126919A (en)	1997-02-07	2000-10-03	3M Innovative Properties Company	Biocompatible compounds for pharmaceutical drug delivery systems
KR100568654B1 (ko)	1997-03-18	2006-04-07	스미스클라인비이참피이엘시이	치환된 이소퀴놀린 유도체 및 진경제로서의 그의 용도
AUPO622597A0 (en)	1997-04-15	1997-05-08	Fujisawa Pharmaceutical Co., Ltd.	New heterocyclic compounds
JPH11174621A (ja)	1997-10-08	1999-07-02	Fuji Photo Film Co Ltd	熱現像写真感光材料
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
EP1131059B1 (de)	1998-11-13	2003-03-05	Jago Research Ag	Trockenpulver zur inhalation
DE69936268T2 (de)	1999-03-05	2008-02-14	Chiesi Farmaceutici S.P.A.	Verbesserte pulverförmige pharmazeutische Zusammensetzungen zur Verwendung in Trockenpulverinhalatoren
US6291476B1 (en)	1999-05-12	2001-09-18	Ortho-Mcneil Pharmaceutical, Inc.	Pyrazole carboxamides useful for the treatment of obesity and other disorders
EP1218336A2 (en)	1999-09-20	2002-07-03	Takeda Chemical Industries, Ltd.	Melanin concentrating hormone antagonist
CA2325358C (en)	1999-11-10	2005-08-02	Pfizer Products Inc.	7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino\|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
US6531478B2 (en)	2000-02-24	2003-03-11	Cheryl P. Kordik	Amino pyrazole derivatives useful for the treatment of obesity and other disorders
US20020052312A1 (en)	2000-05-30	2002-05-02	Reiss Theodore F.	Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AU8066701A (en)	2000-07-20	2002-02-05	Neurogen Corp	Capsaicin receptor ligands
JP4436041B2 (ja)	2000-08-05	2010-03-24	グラクソグループリミテッド	抗炎症剤としての６α，９α−ジフルオロ−１７α−［（２−フラニルカルボキシル）オキシ］−１１β−ヒドロキシ−１６α−メチル−３−オキソ−アンドロスト−１，４−ジエン−１７−チオカルボン酸Ｓ−フルオロメチルエステル
US20020193393A1 (en)	2001-03-07	2002-12-19	Michel Pairet	Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
DE10110772A1 (de)	2001-03-07	2002-09-12	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0031179D0 (en)	2000-12-21	2001-01-31	Glaxo Group Ltd	Nitric oxide synthase inhibitors
GB0103630D0 (en)	2001-02-14	2001-03-28	Glaxo Group Ltd	Chemical compounds
ATE365720T1 (de)	2001-03-08	2007-07-15	Glaxo Group Ltd	Agonisten von beta-adrenorezeptoren
ATE381537T1 (de)	2001-03-22	2008-01-15	Glaxo Group Ltd	Formanilid-derivative als beta2-adrenorezeptor- agonisten
GB0118373D0 (en)	2001-07-27	2001-09-19	Glaxo Group Ltd	Novel therapeutic method
SI1425001T1 (sl)	2001-09-14	2009-04-30	Glaxo Group Ltd Glaxo Welcome	Fenetanolaminski derivati za zdravljenje respiratornih bolezni
GB0123951D0 (en)	2001-10-05	2001-11-28	Glaxo Group Ltd	Therapies for treating respiratory diseases
GB0201677D0 (en)	2002-01-25	2002-03-13	Glaxo Group Ltd	Medicament dispenser
GB0204719D0 (en)	2002-02-28	2002-04-17	Glaxo Group Ltd	Medicinal compounds
GB0208608D0 (en)	2002-04-13	2002-05-22	Glaxo Group Ltd	Composition
DE60318193T2 (de)	2002-04-25	2008-12-04	Glaxo Group Ltd., Greenford	Phenethanolaminderivate
GB0217225D0 (en)	2002-07-25	2002-09-04	Glaxo Group Ltd	Medicinal compounds
GB0220730D0 (en)	2002-09-06	2002-10-16	Glaxo Group Ltd	Medicinal compounds
GB0230045D0 (en)	2002-12-23	2003-01-29	Glaxo Group Ltd	Compounds
PL375993A1 (pl)	2002-09-16	2005-12-12	Glaxo Group Limited	Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitorów fosfodiesterazy
AU2003298094A1 (en)	2002-10-22	2004-05-13	Glaxo Group Limited	Medicinal arylethanolamine compounds
GB0225030D0 (en)	2002-10-28	2002-12-04	Glaxo Group Ltd	Medicinal compounds
EP1556342B1 (en)	2002-10-28	2008-03-26	Glaxo Group Limited	Phenethanolamine derivative for the treatment of respiratory diseases
GB0225540D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
GB0225535D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
EP1677795B1 (en)	2003-10-14	2011-01-05	Glaxo Group Limited	Muscarinic acetycholine receptor antagonists
EP1699512B1 (en)	2003-11-03	2012-06-20	Glaxo Group Limited	A fluid dispensing device
PE20050489A1 (es)	2003-11-04	2005-09-02	Glaxo Group Ltd	Antagonistas de receptores de acetilcolina muscarinicos
AU2004299277A1 (en)	2003-12-19	2005-06-30	Glaxo Group Limited	Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
GB0405933D0 (en) *	2004-03-16	2004-04-21	Glaxo Group Ltd	Compounds
JP2007529464A (ja)	2004-03-16	2007-10-25	グラクソ　グループ　リミテッド	ビラゾロ［３，４−ｂ］ピリジン化合物及びＰＤＥ４阻害剤としてのその使用
GB0405937D0 (en)	2004-03-16	2004-04-21	Glaxo Group Ltd	Compounds
UY28871A1 (es)	2004-04-27	2005-11-30	Glaxo Group Ltd	Antagonistas del receptor de acetilcolina muscarinico
GB0515584D0 (en)	2005-07-28	2005-09-07	Glaxo Group Ltd	Medicament dispenser
WO2007036734A1 (en)	2005-09-29	2007-04-05	Glaxo Group Limited	Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
US20090325952A1 (en) *	2006-08-01	2009-12-31	Glaxo Group Limited	Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors

2007
- 2007-07-31 US US12/375,685 patent/US20090325952A1/en not_active Abandoned
- 2007-07-31 JP JP2009522327A patent/JP2009545579A/ja active Pending
- 2007-07-31 SI SI200730620T patent/SI2046787T1/sl unknown
- 2007-07-31 US US11/831,325 patent/US8003663B2/en not_active Expired - Fee Related
- 2007-07-31 AT AT07766400T patent/ATE504586T1/de active
- 2007-07-31 DE DE602007013762T patent/DE602007013762D1/de active Active
- 2007-07-31 AU AU2007280214A patent/AU2007280214A1/en not_active Abandoned
- 2007-07-31 WO PCT/GB2007/002908 patent/WO2008015416A1/en not_active Ceased
- 2007-07-31 PL PL07766400T patent/PL2046787T3/pl unknown
- 2007-07-31 NZ NZ574533A patent/NZ574533A/en not_active IP Right Cessation
- 2007-07-31 HR HR20110434T patent/HRP20110434T1/hr unknown
- 2007-07-31 DK DK07766400.1T patent/DK2046787T3/da active
- 2007-07-31 CA CA002659539A patent/CA2659539A1/en not_active Abandoned
- 2007-07-31 EP EP07766400A patent/EP2046787B1/en not_active Not-in-force
- 2007-07-31 PT PT07766400T patent/PT2046787E/pt unknown
- 2007-08-01 WO PCT/GB2007/002935 patent/WO2008015437A1/en not_active Ceased
- 2007-08-01 US US12/375,695 patent/US20090318494A1/en not_active Abandoned
- 2007-08-13 CL CL200702349A patent/CL2007002349A1/es unknown
- 2007-08-22 TW TW096131112A patent/TW200840818A/zh unknown
2011
- 2011-06-28 CY CY20111100623T patent/CY1111625T1/el unknown

Also Published As

Publication number	Publication date
NZ574533A (en)	2011-05-27
AU2007280214A1 (en)	2008-02-07
US8003663B2 (en)	2011-08-23
HK1127603A1 (en)	2009-10-02
US20090325952A1 (en)	2009-12-31
WO2008015416A1 (en)	2008-02-07
EP2046787A1 (en)	2009-04-15
TW200840818A (en)	2008-10-16
EP2046787B1 (en)	2011-04-06
WO2008015437A1 (en)	2008-02-07
PT2046787E (pt)	2011-06-15
US20080058369A1 (en)	2008-03-06
CL2007002349A1 (es)	2008-10-10
DK2046787T3 (da)	2011-07-18
CA2659539A1 (en)	2008-02-07
ATE504586T1 (de)	2011-04-15
US20090318494A1 (en)	2009-12-24
DE602007013762D1 (de)	2011-05-19
SI2046787T1 (sl)	2011-07-29
HRP20110434T1 (hr)	2011-08-31
CY1111625T1 (el)	2015-10-07
JP2009545579A (ja)	2009-12-24

Publication	Publication Date	Title
CY1111625T1 (el)	2015-10-07	Ενωσεις πυραζολο[3,4-β]πυριδινης και χρηση αυτων ως αναστολεις pde4
TNSN08104A1 (en)	2009-07-14	Pyrimidine amide compounds as pgds inhibitors
TW200500364A (en)	2005-01-01	Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
CY1109619T1 (el)	2014-08-13	ΕΝΩΣΕΙΣ ΠΥΡΑΖΟΛΟ [3,4-b] ΠΥΡΙΔΙΝΗΣ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΩΣ ΑΝΑΣΤΟΛΕΩΝ ΦΩΣΦΟΔΙΕΣΤΕΡΑΣΗΣ
GEP20104973B (en)	2010-04-26	Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
SG179437A1 (en)	2012-04-27	Pyrimidine hydrazide compounds as pgds inhibitors
NZ587039A (en)	2013-01-25	6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
NZ601267A (en)	2014-03-28	Fused heteroaromatic pyrrolidinones as syk inhibitors
TNSN08478A1 (en)	2010-04-14	Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders
NO20063340L (no)	2006-09-12	Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer
WO2005021515A3 (en)	2005-08-25	Inhibitors of phosphodiesterase type-iv
WO2007071313A3 (en)	2007-10-11	Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
NZ599099A (en)	2013-05-31	Phenyloxadiazole derivatives as pgds inhibitors
WO2008035315A3 (en)	2008-12-04	Inhibitors of phosphodiesterase type-iv
JP2011519845A5 (pl)	2012-06-21
TW200610529A (en)	2006-04-01	Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
MY135776A (en)	2008-06-30	PYRAZOLO [3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
MX2007011079A (es)	2007-10-08	Derivados de diaza-espiro-[4-4]-nonano como antagonistas de la neurocinina (nk1).
PE20081835A1 (es)	2009-01-16	COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA Y SU USO COMO INHIBIDORES DE LA PDE4
TH104555A (th)	2010-10-27	สารประกอบไพราโซโล[3,4-b]ไพริดีน และการใช้ของมันเป็นตัวยับยั้ง PDE4
TH151346A (th)	2016-05-19	การใช้อนุพันธ์ไพเพอริดิน-4-อิลอะเซติดีนเป็นสารยับยั้ง jak1
TH104555B (th)	2010-10-27	สารประกอบไพราโซล[3,4-b]ไพริดีน และการใช้ของมันเป็นตัวยับยั้ง PDE4
TH87151A (th)	2007-10-19	สารประกอบเคมี